From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search

Bevacizumab (beh-vuh-SIH-zoo-mab)A drug used alone or with other drugs to treat certain types of cervical, colorectal, lung, and kidney cancer, and glioblastoma (a type of brain cancer). It is used under the brand name Mvasi to treat these cancers.


Bevacizumab is also used under the brand name Avastin to treat these cancers and to treat certain types of ovarian epithelial, fallopian tube, and primary peritoneal cancer.

VEGF binder

It is also being studied in the treatment of other types of cancer. Bevacizumab binds to a protein called vascular endothelial growth factor (VEGF). This may prevent the growth of new blood vessels that tumors need to grow.

Monoclonal antibody

Bevacizumab is a type of antiangiogenesis agent and a type of monoclonal antibody.

Clinical use of Bevacizumab

Bevacizumab is a humanized monoclonal antibody to human vascular endothelial growth factor (VEGF) and an anti-angiogenesis agent used in the therapy of colorectal, ovarian, renal and brain cancers. 

Liver safety of Bevacizumab

Bevacizumab has not been linked to serum enzyme elevations during therapy or to idiosyncratic acute liver injury.  Bevacizumab may be partially protective against the vascular hepatic damage caused by other chemotherapeutic agents. 

Mechanism of action of Bevacizumab

Bevacizumab (be” va siz’ ue mab) is a recombinant humanized monoclonal IgG1 antibody which is directed at and binds avidly to circulating vascular endothelial growth factor (VEGF).  Receptors for VEGF (Flt-1 and KDR) are present on endothelial cells, and the engagement of VEGF with these receptors promotes angiogenesis.  Inhibition of VEGF decreases formation of new blood vessels, which plays an important role in growth and spread of cancer cells.  When used in combination with other antineoplastic agents, bevacizumab has been shown to extend both recurrence-free as well as overall patient survival in several forms of advanced cancer. 

FDA approval information for Bevacizumab

Bevacizumab was approved in the United States in 2004 for use in metastatic colon cancer.  Indications were subsequently extended to selected forms of non-small cell lung cancer, breast and renal cancer and glioblastoma.  However, the indication for use in breast cancer was withdrawn in 2011 because of lack of evidence that bevacizumab extended overall patient survival. 

FDA approval information for Bevacizumab

Bevacizumab is available vials of 100 or 400 mg (25 mg/mL) under the brand name Avastin.  The typical dose is 5 to 10 mg/kg intravenously every 2 weeks or 7.5 to 15 mg every three weeks, usually in combination with other antineoplastic agents.  Bevacizumab should be administered only by physicians with experience in using antineoplastic agents and managing their major complications.  Bevacizumab has significant adverse side effects

Side effects of Bevacizumab

Common adverse events include epistaxis, headache, dizziness, fatigue, hypertension, rhinitis, dry skin, back pain, excessive bleeding and skin rash.  Rare complications include bowel, stomach or nasal septum perforation, poor wound healing, hemorrhage, thrombosis, renal dysfunction and ovarian failure.

Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ


Cost and Coupons - Bevacizumab

Reviews for Bevacizumab

Learn more about Bevacizumab

Latest research - Bevacizumab

Clinical trials

External links

Medicine icon
Medicine icon

This WikiMD article Bevacizumab is a stub. If you are familiar with the topic Bevacizumab, you can help us. Paid editors welcome!


Bevacizumab is part of WikiMD's free ^articles!

^Bevacizumab (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Overweight?. W8MD's physician weight loss & sleep medicine program can HELP. Philadelphia lose weight. NYC lose weight Tele weight loss available